Two cases (1 woman, and 1 man; 28 and 18 years old, respectively) with first-onset, drug naïve MDD with PD were enrolled. They all received clinical rating scales, with scores as follows: Hamilton Rating Scale for Depression (Ham-D): 30, 24; and Panic Disorder Severity Scale (PDSS): 20, 18. The treatment with duloxetine 30 mg/day was started and titrated to 60 mg within 2 weeks without any significant side effects except mild nausea and sedation. After a 6-week therapy, their MDD and PD symptoms responded to duloxetine [Ham-D: 4, 5; PDSS: 2, 1]. RFMRI scans were obtained with a 3T GE version scanner. Echo planar imaging (EPI) sequences were acquired in 20 axial slices (TR=2,000 msec, TE=40 msec, flip angle=90°, FOV=24 cm; 5-mm thickness and 1 mm gap; 400 sec for each subject) at baseline and 6th week visit. RFMRI data were first preprocessed by DPARSF (Data Processing Assistant and Resting-State FMRI, Version 1.4), which included slice timing, realignment, normalization, smoothing by 4 × 4 × 4 kernel, detrend and filter RFMRI, with data within 0.008–0.08 Hz. The preprocessed RFMRI data were then processed by GIFT (Group Independent Component Analysis of FMRI Toolbox, Version 1.3 hour), and subsequently compared analysis between baseline and the 6th week (uncorrected p<0.00005; voxel threshold >50). There were modest increases of RFMRI brain activities after duloxetine treatment (Table 1).
TABLE 1.Changes of RFMRI brain activities after a 6-week duloxethine therapy